Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Xenon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01486446
First received: December 2, 2011
Last updated: March 10, 2014
Last verified: March 2014

December 2, 2011
March 10, 2014
December 2011
April 2012   (final data collection date for primary outcome measure)
Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 [ Time Frame: 14-21 Days ] [ Designated as safety issue: No ]

Using diary cards, subjects recorded the use of all non-pharmacological cooling methods used to relieve their erythromelalgia (EM) pain each day during Treatment Period 2.

A smaller average number of cooling uses each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa.

Difference in pain intensity from pre-treatment to end of treatment based on an 11-point NRS scale (0-10, where 0=no pain and 10=worst pain you can imagine) [ Time Frame: 5 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01486446 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
  • Average Cooling Duration (Minutes Per Day) for EM-related Pain in Treatment Period 2 [ Time Frame: 14-21 Days ] [ Designated as safety issue: No ]

    Using diary cards, subjects recorded the use and duration of all non-pharmacological cooling methods used to relieve their EM pain each day during Treatment Period 2.

    A smaller average duration of cooling each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa.

  • Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 1, Compared to Baseline [ Time Frame: Baseline to Day 5 ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit".

    A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.

  • Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline and 14 or 21 days ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit".

    A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.

  • Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 1, Compared to Baseline [ Time Frame: Baseline to Day 5 ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable.

    A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain".

    A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.

  • Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline and 14 or 21 days ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable.

    A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain".

    A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.

  • Daily Pain (Maximum Pain Intensity) in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline to 14 or 21 days ] [ Designated as safety issue: No ]

    During Baseline and Treatment Period 2, subjects recorded pain scores in their diary cards 3 times each day (upon waking, lunchtime and evening).

    On each recording occasion, subjects recorded the maximum pain experienced since the previous recording occasion using an 11 point numerical rating scale of pain intensity, PINRS (where 0 = no pain and 10 = worst pain imaginable).

    A lower score compared to Baseline indicates that the subjects experienced less severe pain on treatment than during Baseline.

  • Sleep Interference Due to Pain in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline to 14 or 21 days ] [ Designated as safety issue: No ]

    During Baseline and Treatment Period 2, subjects recorded sleep interference scores in their diary cards for each night (scores were recorded upon waking).

    Sleep Interference due to pain is scored using an 11 point numerical rating scale where 0 = pain does not interfere with sleep and 10 = completely interferes, unable to sleep due to pain.

    A lower sleep interference score compared to Baseline indicates that the subjects' pain interfered with sleep less on treatment than during Baseline.

Not Provided
 
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia

This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM). The purpose of this study is to determine whether XPF-002 is safe and effective in the treatment of pain caused by IEM.

Your role in the study would include:

  • Travelling to the clinic (in Anniston, Alabama, USA) for 3 out-patient visits, each lasting approximately 1 day
  • Travelling and staying in the clinic for 2 in-patient stays:
  • For the first in-patient visit you will have to spend 8 days and 7 nights in the clinic
  • For the second in-patient visit you will have to spend 2 days and 1 night in the clinic You can bring books, laptops and DVDs to the clinic.

If you do not live within driving distance to the clinic you will need to stay in the local area (in Anniston, at a local hotel) for 1 to 2 weeks while you use the ointment, in addition to the in-patient portion of the study.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Primary Erythromelalgia
  • Inherited Erythromelalgia
  • Drug: XPF-002
    XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
  • Drug: Placebo
    XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
  • Experimental: XPF-002
    XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
    Intervention: Drug: XPF-002
  • Placebo Comparator: Placebo
    XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
May 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have a Body Mass Index (BMI) of 18-40 kg/m2 (inclusive)
  • Have primary or inherited erythromelalgia (IEM)
  • Experience flares of pain in your feet or hands caused by erythromelalgia
  • Be generally healthy (apart from your pain)
  • Stop taking your usual pain medications and certain other medications for up to 11.5 weeks
  • Not be pregnant or breast-feeding
  • Must be able and willing to provide informed consent and willing to comply with all study procedures and restrictions

Exclusion Criteria:

  • Must not be in constant pain (must not continually be in moderate pain, 3/10 or more)
  • Coexistent source of pain from other conditions that may interfere with the study interpretation
  • HIV, Hepatitis B or C
  • Treatment for significant depression within 6 months of Screening
  • Not willing to use adequate contraception
  • Alcoholism, alcohol or substance abuse
  • Presence or history of major psychiatric disturbance
  • Any other condition or finding that may pose undue risk for participation
  • Use of any other investigational drug in the 30 days prior to dosing
  • Donation or loss of whole blood or plasma prior to dosing as follows: 50 mL to 499 mL within 30 days, or more than 499 mL within 56 days
  • Employee or relative of an employee who is directly involved in the study
Both
19 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01486446
XPF-002-202
No
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.
Not Provided
Principal Investigator: Almena L Free, MD Pinnacle Research Group LLC.
Xenon Pharmaceuticals Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP